01 JUNE 2019 03 JUNE 2019

Event Title: ASCO 2019
June 1-3, 2019
McCormick Place, 2301 S King Drive, Chicago, IL 60616

Visit Roche Diagnostics Oncology Solutions at Booth #20005

Town Hall
Friday, May 31 | 03:30 pm - 05:30 pm
Grand Ballroom, Level 7, Chicago Marriott Downtown Magnificent Mile

Multidisciplinary Management of Complex Lung Cancer in the Era of Precision Oncology
Panel Chair: Alice Shaw, MD, PhD
June 1 | 6:30–8:00pm
Marriott Marquis Hotel
Grand Horizon Ballroom, Level 4


NAVIFY® Tumor Board

Developed as a result of the collaboration between Roche and GE Healthcare, NAVIFY Tumor Board is a cloud-based workflow product that securely integrates and displays relevant aggregated data into a single, holistic patient dashboard for oncology care teams to review, align and decide on the optimal treatment for the patient.

Learn More

NAVIFY® Mutation Profiler*

A clinical NGS reporting solution that can help labs accurately and efficiently interpret the clinical significance of mutations, empowering clinicians to deliver more personalized healthcare.

*Not yet commercially available in the US

Learn More

cobas® EGFR Mutation Test v2

The only FDA-approved diagnostic test for NSCLC using liquid biopsy.
Companion diagnostic for Tarceva® (erlotinib), IRESSA® (gefitinib) & TAGRISSO® (osimertinib)

AVENIO NGS Assays for Clinical Research**

Liquid biopsy and tumor tissue assays for comprehensive genomic profiling, surveillance & monitoring AVENIO NGS assays are for Research Use Only. Not for Use in Diagnostic Procedures.

Learn More

**Research Use Only. Not for use in diagnostic procedures. 
AVENIO, COBAS and NAVIFY are a trademarks of Roche. All other product names and trademarks are the property of their respective owners.